Please assess the completion status of the following clinical trial:

Trial Title: Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria~* In AML defined by cytogenetic aberrations the proportion of blasts may be \<20%~* Age ≥60 years~* Clinical performance corresponding to ECOG score 0-2~* High-risk karyotype~* \<5% myeloblasts in bone marrow ≥21 days after beginning of most recent chemotherapy~* maximal two preceding chemotherapy cycles~* Potentially available haploidentical family donor (child/ sibling), willing and fit for NK cell donation~Exclusion Criteria:~* AML with favorable or intermediate risk cytogenetic features~* Persistent aplasia following preceding chemotherapy~* Relapsed or refractory AML~* Known pre-existing autoimmune diseases~* Any severe concomitant condition which makes it undesirable for the patient to participate in the study~* Any condition which could jeorpadize compliance of the protocol~* Participation in another clinical trial during or within 4 weeks before study entry

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- NK cells (Type: EXPERIMENTAL): Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
- Control Intervention (Type: ACTIVE_COMPARATOR): 1 cycle of consolidation chemotherapy with high-dose cytarabine

Based on this trial design, predict the completion outcome and termination type (if applicable).